Abstract 1568P
Background
To increase the effectiveness of the treatment, radiotherapy (RT) is frequently combined with chemotherapy, immunotherapy, or radiosensitizer medications. Identifying a patient’s radiosensitivity can be important for determining patient’s therapy strategy. But there isn’t a reliable and pertinent radiation sensitivity prediction model for assessing radiation sensitivity. Here, we propose the cancer organoid-based platform for predicting the individual RT response evaluation and recurrence.
Methods
Eighteen Esophageal cancer biopsy tissues were dissociated to single cells and then disposed with BME on pillar plate (MBD co., Korea) to make the cancer organoids. After forming the organoids, these were exposed to radiation doses of 2, 4 and 8Gy. We are staining live organoid with calcein AM after radiation and obtain organoid viability. From viability, AUC (area under curve) and growth rate were calculated to predict patient’s radiation sensitivity. With these two variables, the patient's cancer stage score was also used to predict patient’s radiation sensitivity. CODRP (cancer organoid-based diagnosis reactivity prediction), radiosensitivity predication index, were calculated by patient’s AUC, growth rate, and cancer stage.
Results
Radiation sensitivity prediction model using each single-factor (patient’s AUC, growth rate and cancer stage) showed about 62% specificity, 72% sensitivity and positive predictive value (PPV) was 69%. However, when applying multi-factor model (CODRP), the specificity was 81.8%, the sensitivity was 85.7%, and the PPV was 90%. In the CODRP model, the radiation sensitive group showed 11.1% recurrence rate, while the radiation resistive group showed 72.7% recurrence rate. Therefore, there was a significant difference in recurrence-free survival rate between the sensitive group and the non-responder group based on the CODRP model.
Conclusions
Our proposed CODRP models using patient derived cancer organoid successfully predict clinical response of patient’s radiation treatment. Thus, this platform has promise as a novel prognostic indicator for people with esophageal cancer and can support precision treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21